Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

August 30, 2024
Comparison of POSEIDON Pivotal Cohort vs. NACSELD-III Supports Strong Commercial Messaging for alfapump Poster presentation by Dr. Jasmohan S. Bajaj on 7 June 2024 Ghent, Belgium – 10 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES